Text Size

Dyslipidemia in Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00547274
First received: October 19, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted
  Purpose

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).


Condition Intervention Phase
Diabetes Mellitus, Type II
Dyslipidemia
 Drug: MK0767
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Merck:

Study Start Date: May 2003
Study Completion Date: May 2004
  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and non-pregnant females
  • Age greater than or equal to 21 years
  • Stop current diabetes therapy (if applicable)
  • Stop current statin therapy (if applicable)

Exclusion Criteria:

  • History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
  • Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
  • Patients requiring treatment with corticosteroids for more than 14 consecutive days
  • Patients taking warfarin or warfarin-like anti-coagulants
  • Patients undergoing surgery within 30 days of Visit 1
  • Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
  • Patients with history of pancreatitis or uncontrolled high blood pressure
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00547274

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00547274     History of Changes
Other Study ID Numbers: 2007_635
Study First Received: October 19, 2007
Last Updated: October 19, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Dyslipidemias
Glucose Metabolism Disorders
 Metabolic Diseases
Endocrine System Diseases
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on May 19, 2013